Irish Examiner on MSN9h
On the rebound: What are the long-term risks of Ozempic?Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...
We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...
Consumer Reports warns there are important considerations, especially for older adults, before starting these treatments.
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...
The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...
Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
When Trova Wine and Market in Dallas shut its doors last month after nearly five years in business, owner Michelle Bonds ...
People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback